Capsule endoscopy (CE), introduced in 2000 and FDA-approved in 2001, remains a valuable tool for diagnosing gastrointestinal (GI) lesions, particularly in areas inaccessible to traditional endoscopy. While CE offers non-invasive imaging and improves detection of small bowel diseases and obscure GI bleeding, its widespread use is hindered by limitations such as lack of therapeutic capabilities, inability to obtain biopsies, reliance on peristalsis for movement, and time-consuming image interpretation.
Trending
- U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer (Pfizer)
- Oshi Health’s 2025 Impact Report Demonstrates Exceptional GI Outcomes and Cost Savings at Scale (PR Newswire)
- Medtronic announces CE Mark for the next generation GI Genius™ module and ColonPRO™ software (Medtronic)
- Allurion gets FDA nod for weight loss balloon (Mass Device)
- The 7 Must-Haves For The Doctor Of the 21st Century (The Medical Futurist)
- Will AI Eventually De-Skill Doctors? The Evidence Is Trickling In (Forbes)
- CRC Screening by Colonoscopy and FIT Improves Early Detection over Usual Care (Inside Precision Medicine)
- It’s Called the ‘Fitbit for Farts’—and It’s No Joke (The Wall Street Journal)
